The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …

The molecular features that define clear cell renal cell carcinoma (ccRCC) initiation and
progression are being increasingly defined. The TRACERx Renal studies and others that …

Clear cell renal cell carcinomas (ccRCCs) represent∼ 75% of RCC cases and account for
most RCC-associated deaths. Inter-and intratumoral heterogeneity (ITH) results in varying …

Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4
(CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success …

Abstract The Genitourinary Pathology Society (GUPS) reviewed recent advances in renal
neoplasia, particularly post-2016 World Health Organization (WHO) classification, to provide …

Renal cell carcinoma (RCC) is not a single disease, but several histologically defined
cancers with different genetic drivers, clinical courses, and therapeutic responses. The …

Immune checkpoint inhibitors targeting the programmed cell death 1 receptor (PD-1)
improve survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). To …

Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and
accounts for> 90% of cancers in the kidney. The disease encompasses> 10 histological and …

To elucidate the deregulated functional modules that drive clear cell renal cell carcinoma
(ccRCC), we performed comprehensive genomic, epigenomic, transcriptomic, proteomic …

The evolutionary features of clear-cell renal cell carcinoma (ccRCC) have not been
systematically studied to date. We analyzed 1,206 primary tumor regions from 101 patients …